B cells and how they influence response of operable lung cancer to pre-surgery immunotherapy
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
This project looks at whether B cells in and around tumors help people with operable non-small cell lung cancer respond better to immunotherapy given before surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11146422 on NIH RePORTER |
What this research studies
If you have operable non-small cell lung cancer, researchers will study tumor tissue collected around the time of pre-surgery chemoimmunotherapy to map where B cells and immune structures sit in the tumor. They will use advanced spatial-omics and molecular analyses to compare samples from people who had strong responses to those who did not. The team will combine data from recent clinical trials to find immune patterns and potential biomarkers linked to benefit. The ultimate aim is to guide new drug combinations that reduce resistance and help more patients get meaningful benefit from pre-surgery immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates are people with resectable (operable) non-small cell lung cancer who are receiving or eligible for pre-surgery chemoimmunotherapy.
Not a fit: People with unresectable or widely metastatic lung cancer, other cancer types, or those not getting pre-surgery immunotherapy are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could identify who is most likely to benefit from neoadjuvant immunotherapy and point to new combination treatments that improve outcomes for patients with resectable NSCLC.
How similar studies have performed: Earlier trials such as NEOSTAR and NeoCOAST found higher B cell levels and tertiary lymphoid structure signals in responders, so this work builds on promising preliminary findings.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Cascone, Tina — University of Tx Md Anderson Can Ctr
- Study coordinator: Cascone, Tina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.